Cytokines in Alzheimer's Disease and Vascular Dementia

Angelopoulos, Pavlos; Agouridaki, H; Vaiopoulos, H; Siskou, E; Doutsou, K; Costa, Vassiliki; Baloyiannis, S.

doi:10.1080/00207450701392068

Cited by 86 publications

(60 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with our present results, several reports based on genome-wide association studies have shown upregulation of the IL-10 pathway in AD brains [16,17]. Furthermore, several previous studies have found increased CSF and blood levels of IL-10 in AD patients compared to healthy controls [9,18,19,20]. Indeed, IL-10 serum levels have been associated with the degree of cognitive decline and cortical atrophy in AD patients and as a consequence many authors have considered IL-10 as a potential marker of disease progression [21].…”

Section: Discussionsupporting

confidence: 82%

“…It is a prototypic proinflammatory cytokine and a key regulator of local tissue responses to injury and disease in the CNS [28]. Our results confirm previous findings documenting increased levels of IL-1β in brain lesions, CSF [28,29], and blood of AD patients [6,19,30,31,32,33,34]. IL-1β is supposed to have both beneficial and detrimental effects on the AD pathogenesis.…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients

D’Anna

Abu‐Rumeileh²,

Fabris³

et al. 2017

Neurodegener Dis

View full text Add to dashboard Cite

Background and Objective: In Alzheimer disease (AD) inflammation becomes evident throughout the course of the disease. However, the association between inflammation, cognitive impairment, and cerebrospinal biomarkers (Aβ42, t-tau, p-tau181, and Aβ42/p-tau181 ratio) is poorly understood. Methods: A large panel of inflammatory cytokines (interleukin [IL]-1β, IL-1ra, IL-2, IL-4, IL-6, IL-10, IL-17, interferon-γ, tumor necrosis factor-α, and vascular endothelial growth factor) was analyzed using a multiplex immunoassay in 27 patients with a diagnosis of AD dementia and in 18 control subjects. In a subgroup with available cerebrospinal fluid (CSF) samples, cytokines in serum were correlated with the levels of neurodegenerative CSF biomarkers (Aβ42, t-tau, p-tau181, and Aβ42/p-tau181 ratio). Results: Compared to control subjects, AD patients showed a significant upregulation of IL-10, IL-1β, and IL-17 serum levels. Several cytokines appeared intercorrelated, and IL-10 in particular presented a significant inverse correlation with CFS levels of Aβ42 and the Aβ42/p-tau ratio. Conclusion: Our findings indicate that serum levels of IL-10 may represent a possible peripheral expression of amyloid beta deposition in AD patients.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 81%

Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients

D’Anna

Abu‐Rumeileh²,

Fabris³

et al. 2017

Neurodegener Dis

View full text Add to dashboard Cite

show abstract

“…It has been reported that level of IL-10 is elevated in the serum of patients with dementia but these levels do not discriminate between different types of dementia [133]. One of the mechanisms attributed to the role of IL-10 in reducing inflammation in AD is suppression of pro-inflammatory cytokines.…”

Section: Interleukin-4 (Il-4)mentioning

confidence: 99%

Genetic and Blood Biomarkers of Alzheimer`s Disease

Momeni¹,

Ferrari²

2010

TONMEDJ

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most prevalent form of dementia. AD is highly heritable, with a complex pattern. Although clinical diagnosis is based on accurate and well defined diagnostic criteria (NINCDS-ADRDA), the definite diagnosis relies on the postmortem pathological findings. The need for measures for the early detection of AD, as well as the need to distinguish between AD and other forms of dementia, has put great emphasis on the discovery of biomarkers for Alzheimer's disease. In clinical practice, there is need for non-invasive, accurate methods for the early detection and differential diagnosis of AD. The successful identification and development of the biomarkers, depends completely on the understanding of pathology, genetic and molecular mechanisms involved in the disease. As blood is a circulating dynamic tissue and transcription reflects the ongoing changes in the system, it makes the transcriptional profiling of the blood cells, potentially, the most sensitive source for transcriptional biomarkers. A systematic comparison of the genetic and proteomic blood biomarkers in patients and healthy controls can reveal additional potential candidates for AD. In the first part of this review, we would like to discuss the most recent genetic findings and their possible involvement in the pathogenesis of AD. In the second part, we review the blood biomarkers which can be derived from peripheral blood mononuclear cells (PBMC), serum, and plasma. We discus three main category of bio-molecules, namely DNA, RNA (miRNA and mRNA), and protein as well as their possible role in the hypothetical mechanisms involved in pathogenesis of AD. A dynamic interaction between the genetic findings through the whole genome association studies and biomarkers discovery can advance our knowledge of AD pathogenesis beyond the scope of each field independently.

show abstract

“…Many studies revealed a high level of proinflammatory cytokines in the blood of patients with AD [7][8][9]. Other authors reported a decrease [10] or no change of these indices level compared to control [11].…”

Section: Introductionmentioning

confidence: 99%

A comparative study of innate immunity markers in Alzheimer's disease, Mixed dementia and Vascular dementia

Андросова¹,

Mikhaylova²,

Zozulya³

et al. 2016

IJCNMH

View full text Add to dashboard Cite

Background: Innate immunity is currently considered to be an important component of pathological cascade in old age dementia. The aim of this study was to evaluate activity of inflammatory markers such as leukocyte elastase and alpha-1 proteinase inhibitor, as well as concentration of C-reactive protein and interleukin-6 in blood plasma of patients with pure' AD, mixed dementia and VaD of varying severity.Methods: Several parameters of innate immunity such as leukocyte elastase activity (LE), the functional activity of α1-proteinase inhibitor, the concentration of C-reactive protein (CRP) and interleukin-6 (IL-6) were measured in blood plasma of elderly patients with main forms of dementia including: Alzheimer's disease (AD), mixed dementia (MD) and vascular dementia (VaD). Results:A total of 161 in-patients and 39 control subjects were included in the study. The levels of innate immunity markers were found to depend on the severity of dementia. The decreased activity of LE in AD and MD is suggested to be due to the alteration of neutrophils degranulation activity or to changes in enzyme properties. A negative correlation between the level of IL-6 and degree of cognitive impairment in AD (Spearman r= -0.43; p<0.05) indicates significantly that levels of proinflammatory cytokines may characterize the severity of the process having the great impact on (lower) total MMSE score. Elevated level of CRP is likely to be a biological marker of an early stage of disease in VaD. Conclusions AbstractA comparative study of innate immunity markers in Alzheimer's disease, Mixed dementia and Vascular dementia 2 ARC Publishing

show abstract

Cytokines in Alzheimer's Disease and Vascular Dementia

Cited by 86 publications

References 30 publications

Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients

Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients

Genetic and Blood Biomarkers of Alzheimer`s Disease

A comparative study of innate immunity markers in Alzheimer's disease, Mixed dementia and Vascular dementia

Contact Info

Product

Resources

About